TERBINAFINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Terbinafine Hydrochloride patents expire, and when can generic versions of Terbinafine Hydrochloride launch?
Terbinafine Hydrochloride is a drug marketed by Taro, Aurobindo Pharma, Breckenridge Pharm, Chartwell, Cipla, Dr Reddys Labs Inc, Emed Medcl, Gedeon Richter Usa, Glenmark Generics, Heritage Pharma Avet, Invagen Pharms, Mylan, Orbion Pharms, Roxane, and Wockhardt. and is included in sixteen NDAs.
The generic ingredient in TERBINAFINE HYDROCHLORIDE is terbinafine hydrochloride. There are twenty-seven drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the terbinafine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Terbinafine Hydrochloride
A generic version of TERBINAFINE HYDROCHLORIDE was approved as terbinafine hydrochloride by TARO on July 2nd, 2007.
Summary for TERBINAFINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 15 |
NDAs: | 16 |
Finished Product Suppliers / Packagers: | 39 |
Raw Ingredient (Bulk) Api Vendors: | 115 |
Clinical Trials: | 45 |
Patent Applications: | 1,829 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TERBINAFINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for TERBINAFINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Dhaka Medical College | Phase 2/Phase 3 |
Moberg Pharma AB | Phase 3 |
IQVIA Biotech | Phase 3 |
Pharmacology for TERBINAFINE HYDROCHLORIDE
Drug Class | Allylamine Antifungal |